Aliases & Classifications for Excessive Tearing

MalaCards integrated aliases for Excessive Tearing:

Name: Excessive Tearing 12 15 74
Lacrimal Apparatus Diseases 45 74
Epiphora 12 15
Excessive Tear Production 12
Watering Eye 12

Classifications:



External Ids:

Disease Ontology 12 DOID:13757
ICD9CM 36 375.2 375.20
MeSH 45 D007766
NCIt 51 C50552
SNOMED-CT 69 49393005
ICD10 34 H04.2 H04.20

Summaries for Excessive Tearing

MalaCards based summary : Excessive Tearing, also known as lacrimal apparatus diseases, is related to dacryocystitis and early-onset glaucoma, and has symptoms including visual disturbance, eye manifestations and discharge from eye. An important gene associated with Excessive Tearing is DCXR (Dicarbonyl And L-Xylulose Reductase). The drugs Hyaluronic acid and Calcium Carbonate have been mentioned in the context of this disorder. Affiliated tissues include eye, salivary gland and testes, and related phenotype is vision/eye.

Related Diseases for Excessive Tearing

Diseases related to Excessive Tearing via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 90)
# Related Disease Score Top Affiliating Genes
1 dacryocystitis 32.2 DCXR EXT1
2 early-onset glaucoma 31.1 CYP1B1 MYOC
3 chronic dacryocystitis 29.8 DCXR EXT1
4 lacrimal apparatus disease 12.5
5 epiphora due to insufficient drainage 12.1
6 epiphora due to excess lacrimation 12.1
7 bell's palsy 11.3
8 aplasia of lacrimal and salivary glands 11.2
9 epithelial recurrent erosion dystrophy 11.1
10 dyskeratosis congenita, autosomal dominant 1 11.1
11 rapp-hodgkin syndrome 11.1
12 dyskeratosis congenita, autosomal dominant 3 11.1
13 acute canaliculitis 11.1
14 corneal dystrophy, epithelial basement membrane 11.0
15 tyrosinemia, type ii 11.0
16 cluster headache 11.0
17 oncocytoma 10.1
18 lymphoma 10.1
19 facial paralysis 10.1
20 dacryoadenitis 10.1
21 acute inflammation of lacrimal passage 10.1 DCXR EXT1
22 atrophic rhinitis 10.0 DCXR EXT1
23 torticollis 10.0
24 ptosis 10.0
25 acute dacryocystitis 10.0
26 ectropion 10.0
27 pleomorphic adenoma 10.0
28 adenoma 10.0
29 exophthalmos 10.0
30 dacryocystocele 10.0
31 chronic inflammation of lacrimal passage 10.0 DCXR EXT1
32 breast cancer 9.9
33 glaucoma 3, primary infantile, b 9.9 CYP1B1 LTBP2
34 kaposi sarcoma 9.9
35 facioscapulohumeral muscular dystrophy 1 9.9
36 lymphoma, hodgkin, classic 9.9
37 myxedema 9.9
38 dyskeratosis congenita, x-linked 9.9
39 lymphoma, non-hodgkin, familial 9.9
40 aneurysmal bone cysts 9.9
41 cataract 9.9
42 marginal zone b-cell lymphoma 9.9
43 sinusitis 9.9
44 adenoid cystic carcinoma 9.9
45 xerophthalmia 9.9
46 chronic maxillary sinusitis 9.9
47 sarcoma 9.9
48 orbital cellulitis 9.9
49 senile ectropion 9.9
50 malignant conjunctival melanoma 9.9

Graphical network of the top 20 diseases related to Excessive Tearing:



Diseases related to Excessive Tearing

Symptoms & Phenotypes for Excessive Tearing

UMLS symptoms related to Excessive Tearing:


visual disturbance, eye manifestations, discharge from eye, dacryops, watery eyes

MGI Mouse Phenotypes related to Excessive Tearing:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 vision/eye MP:0005391 9.02 CYP1B1 EXT1 FGF10 LTBP2 MYOC

Drugs & Therapeutics for Excessive Tearing

Drugs for Excessive Tearing (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 469)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9004-61-9 53477741
2
Calcium Carbonate Approved, Investigational Phase 4 471-34-1
3
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
4
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
5
Prednisone Approved, Vet_approved Phase 4,Phase 3 53-03-2 5865
6
Tocopherol Approved, Investigational Phase 4,Not Applicable 1406-66-2 14986
7
Povidone Approved Phase 4,Phase 3,Not Applicable 9003-39-8
8
Loteprednol Approved, Experimental Phase 4,Phase 3,Phase 2,Not Applicable 82034-46-6, 129260-79-3 9865442 444025
9
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-02-2 5743
10
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1177-87-3
11
Glycerol Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 56-81-5 753
12
Fluorometholone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 426-13-1 9878
13
Hydrocortisone acetate Approved, Vet_approved Phase 4,Not Applicable 50-03-3
14
Hydrocortisone Approved, Vet_approved Phase 4,Not Applicable 50-23-7 5754
15
Fluticasone Approved, Experimental Phase 4,Phase 3,Phase 2 90566-53-3 62924
16
Fexofenadine Approved, Investigational Phase 4,Phase 3 83799-24-0 3348
17
Loratadine Approved, Investigational Phase 4,Phase 3 79794-75-5 3957
18
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-45-6 774
19
Bepotastine Approved Phase 4,Phase 2,Phase 3 190786-44-8, 125602-71-3 2350
20
Cetirizine Approved Phase 4,Phase 2,Phase 3 83881-51-0 2678
21
Levocetirizine Approved Phase 4,Phase 2 130018-77-8 1549000
22
Montelukast Approved Phase 4,Phase 3,Phase 2 158966-92-8 5281040
23
Remifentanil Approved Phase 4 132875-61-7 60815
24
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
25
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
26
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
27
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
28
Ketorolac Approved Phase 4,Phase 2,Phase 3 74103-06-3, 66635-83-4 3826
29
Alcaftadine Approved Phase 4 147084-10-4 19371515
30
Azelastine Approved Phase 4,Phase 3,Phase 2,Not Applicable 58581-89-8 2267
31
Moxifloxacin Approved, Investigational Phase 4,Phase 1 354812-41-2, 151096-09-2 152946
32
Norgestimate Approved, Investigational Phase 4,Phase 1 35189-28-7 6540478
33
Polyestradiol phosphate Approved Phase 4,Phase 2,Phase 1 28014-46-2
34
Ethinyl Estradiol Approved Phase 4,Phase 1 57-63-6 5991
35
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 50-28-2 5757
36
Omalizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 242138-07-4
37
Lifitegrast Approved Phase 4,Phase 3,Phase 2,Not Applicable 1025967-78-5
38
Azithromycin Approved Phase 4 83905-01-5 447043 55185
39
Dimenhydrinate Approved Phase 4,Not Applicable 523-87-5 441281
40
Sorbitol Approved Phase 4,Not Applicable 50-70-4 5780
41
Allantoin Approved Phase 4,Not Applicable 97-59-6 204
42
Sodium Citrate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 68-04-2
43 sodium fluoride Approved Phase 4,Not Applicable 7681-49-4
44
Menthol Approved Phase 4 2216-51-5 16666
45
Zinc Approved, Investigational Phase 4,Phase 2,Not Applicable 7440-66-6 32051
46
Ethanol Approved Phase 4,Phase 3,Phase 2,Not Applicable 64-17-5 702
47
Isotretinoin Approved Phase 4 4759-48-2 5282379 5538
48
Dipivefrin Approved Phase 4,Phase 3,Phase 1 52365-63-6 3105
49
Ofloxacin Approved Phase 4,Phase 3 82419-36-1 4583
50
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2 302-25-0

Interventional clinical trials:

(show top 50) (show all 931)
# Name Status NCT ID Phase Drugs
1 Effect of Intense Pulse Light (IPL) Treatment on Tear Film Osmolarity Unknown status NCT02992535 Phase 4
2 0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients Unknown status NCT02595606 Phase 4 0.3% Sodium Hyaluronate
3 Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome Unknown status NCT02370550 Phase 4 Cyclosporin A;Prednisone;Placebo;Calcium carbonate D
4 Oral Nutrition Impact on Tear Film Unknown status NCT01561040 Phase 4
5 Efficacy of FreshKote and Systane for the Treatment of Dry Eye and Improvement of Osmolarity Unknown status NCT01386073 Phase 4 FreshKote;Systane
6 Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms Unknown status NCT01382810 Phase 4 Altaire Gel forming solution;Refresh Tears
7 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
8 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4 cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
9 Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Unknown status NCT00704275 Phase 4 0.05% cyclosporin eye drop
10 Sex Steroids in Sjögren's Syndrome: Effect of Substitution Treatment on Fatigue Unknown status NCT00543166 Phase 4 dehydroepiandrosterone
11 The Safety and Efficacy of Lacrimal Silicone Intubation for the Management of Epiphora Completed NCT01010659 Phase 4
12 Intranasal Steroids and the Nasal Ocular Response Completed NCT00473915 Phase 4 fluticasone furoate
13 Clinical Assessment of the Total Vaginal Mesh Technique for Treatment of Genital Prolapse Completed NCT00196495 Phase 4
14 A Study of Onset of Action of Loratadine and Fexofenadine in Participants With Seasonal Allergic Rhinitis (P08712) Completed NCT01469234 Phase 4 loratadine;fexofenadine;placebo to loratadine;placebo to fexofenadine
15 Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis Completed NCT01443442 Phase 4 bepotastine besilate, 1.5%;Loteprednol etabonate
16 Effect of Veramyst and Olopatadine 0.2% Opthalmic Solution on Allergy Symptoms Completed NCT01007253 Phase 4 PL nasal spray;fluticasone furoate (FF);PL eye drops;olopatadine (OLO)
17 Randomized Controlled Trial (RCT)Comparing GYNAECARE MORCELLEX Versus ROTOCUT GI Tissue Morcellators Completed NCT00743080 Phase 4
18 Comparability and Standardization of Controlled Allergen Challenge Facilities Completed NCT02543346 Phase 4 Cetirizine
19 Compare the Efficacy of Levocetirizine and Montelukast to Placebo in Reducing Seasonal Allergic Rhinitis (SAR) Symptoms in Ragweed Sensitive Subjects Completed NCT00295022 Phase 4 Placebo;Montelukast;Levocetirizine
20 Topical Cyclosporine for Vernal Keratoconjunctivitis (VKC) in Rwanda Completed NCT01211327 Phase 4 Cyclosporine A;Dexamethasone
21 A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis Completed NCT00653224 Phase 4 levocetirizine dihydrochloride;placebo
22 Recovery After Sugammadex(Propofol vs Sevoflurane) Completed NCT01579851 Phase 4 Sugammadex
23 A Clinical Study To Test A Nasal Spray (Fluticasone Furoate Nasal Spray) For The Treatment Of Perennial (Year-round) Allergic Rhinitis Completed NCT00609674 Phase 4 Fluticasone furoate nasal spray;Placebo
24 Pain Management in Corneal Collagen Crosslinking for Keratoconus Completed NCT02867176 Phase 4 Gabapentin;Ketorolac
25 A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis Completed NCT01470118 Phase 4 alcaftadine 0.25% ophthalmic solution;olopatadine 0.2% ophthalmic solution;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
26 Comparison of Seasonal Allergic Rhinitis Treatment With 2 Antihistamines Used in Combination With Intranasal Corticosteroid Completed NCT00845195 Phase 4 Olopatadine HCl Nasal Spray, 0.6%;Azelastine HCl Nasal Spray, 0.1%
27 Comparison of Olopatadine 0.6% and Fluticasone Proprionate 50mcg Nasal Sprays in a Two Week Seasonal Allergic Rhinitis Trial Completed NCT00691665 Phase 4 Olopatadine HCL Nasal Spray, 0.6%;Fluticasone Propionate Nasal Spray, 50 mcg
28 A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis Completed NCT01732757 Phase 4 Alcaftadine 0.25%;Olopatadine 0.2%;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
29 The Role of Gabapentin in Postoperative Pain and Epithelialization After Photorefractive Keratectomy Completed NCT01177514 Phase 4 Gabapentin;Sugar pill
30 Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment Completed NCT00798577 Phase 4 Vigamox Ophthalmic Solution;BSS placebo
31 A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis Completed NCT01916226 Phase 4 FPNS;FPNS Placebo;Cetirizine;Cetirizine Placebo
32 A Randomised, Double Blind, Placebo Controlled, 4 Period, Incomplete Block, Crossover Study Assessing the Dose-response Curve of Fluticasone Propionate in an Antigen Challenge Chamber Completed NCT00848965 Phase 4 Fluticasone propionate;Placebo
33 Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine Completed NCT00502775 Phase 4 fluticasone furoate, fexofenadine
34 A Study of Omalizumab in Preventing Bronchoconstriction Following Environmental Cat Dander Exposure in Patients With Cat Dander-induced Asthma Completed NCT00495612 Phase 4 Omalizumab;Placebo
35 Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine Completed NCT00435461 Phase 4 Fluticasone furoate and fexofenadine
36 Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis Completed NCT00407043 Phase 4 Lotemax;Restasis
37 A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome Completed NCT02139033 Phase 4 Retaine™
38 Effect of Lifitegrast on Dry Eye Disease Signs and Symptoms Completed NCT03451396 Phase 4 Lifitegrast
39 The Utility of IVCM to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With DED Completed NCT02120079 Phase 4 Lotemax;Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears)
40 A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye Completed NCT02117687 Phase 4 carboxymethylcellulose 0.5%/glycerin 0.9%;sodium hyaluronate 0.18%
41 A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease Completed NCT01014078 Phase 4 Azithromycin Ophthalmic Solution, 1%;Placebo
42 Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye Completed NCT00987727 Phase 4 carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD);sodium hyaluronate 0.18% (VISMED® Multi)
43 Objective Measurements of Prolonged Effects of Restasis on Dry Eye Disease Completed NCT00567177 Phase 4 Restasis, Refresh Plus
44 Bromfenac 0.09% vs Ketorolac 0.4% for Cyclosporine Induction Phase Completed NCT00520260 Phase 4 bromfenac;ketorolac
45 Tear Lipid Layer Thickness With Emollient Eye Drops Completed NCT03380624 Phase 4 Refresh Optive;Refresh Optimum OMEGA 3
46 Evaluation of Tear Osmolarity Over Time With Sustained Use of Thera Tears Lubricating Drops Completed NCT02758327 Phase 4 TheraTears Lubricating Eye Drops
47 Evaluation of Maintaining Visual Performance in Participants Who Engage in Electronic Visual Tasking While Using Restasis® Completed NCT02554981 Phase 4 Cyclosporine 0.05% Ophthalmic Emulsion
48 Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy Completed NCT02121847 Phase 4 cyclosporine 0.05% ophthalmic emulsion;carboxymethylcellulose-based lubricant eye drops
49 Effect of Olixia Pure® Eye Drops on Tear Film Thickness in Healthy Subjects Completed NCT01970917 Phase 4
50 The Effects of BAK on the Blood Aqueous Barrier of Pseudophakic Patients Completed NCT01280110 Phase 4 Hydroxypropylmethylcellulose;Carboxymethylcellulose

Search NIH Clinical Center for Excessive Tearing

Cochrane evidence based reviews: lacrimal apparatus diseases

Genetic Tests for Excessive Tearing

Anatomical Context for Excessive Tearing

MalaCards organs/tissues related to Excessive Tearing:

42
Eye, Salivary Gland, Testes, Thyroid, B Cells, Skin, Heart

Publications for Excessive Tearing

Articles related to Excessive Tearing:

# Title Authors Year
1
Epiphora and canalicular stenosis associated with adjuvant docetaxel in early breast cancer: is excessive tearing clinically important? ( 23650413 )
2013
2
Prevalence of excessive tearing in women with early breast cancer receiving adjuvant docetaxel-based chemotherapy. ( 23650421 )
2013
3
Index of Suspicion. Case 1: Irritability and signs of peritonitis in a neonate. Case 2: Red eye, excessive tearing, photophobia, irritability, and splenomegaly in an infant. Case 3: 2-year-old girl who has cough, right pulmonary abnormalities. ( 22383516 )
2012
4
Epiphora (excessive tearing) and other ocular manifestations related to weekly docetaxel: underestimated dose-limiting toxicity. ( 16645230 )
2006
5
Management of excessive tearing as a side effect of docetaxel. ( 15748466 )
2005
6
Excessive tearing in infancy and early childhood. The role and treatment of congenital nasolacrimal duct obstruction. ( 10865874 )
2000

Variations for Excessive Tearing

Expression for Excessive Tearing

Search GEO for disease gene expression data for Excessive Tearing.

Pathways for Excessive Tearing

GO Terms for Excessive Tearing

Cellular components related to Excessive Tearing according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular matrix GO:0031012 8.32 LTBP2

Biological processes related to Excessive Tearing according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 blood vessel morphogenesis GO:0048514 8.62 CYP1B1 FGF10

Sources for Excessive Tearing

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....